Pulike Biological Engineering Inc
SSE:603566
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pulike Biological Engineering Inc
Tax Provision
Pulike Biological Engineering Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pulike Biological Engineering Inc
SSE:603566
|
Tax Provision
-¥14.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-1%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Tax Provision
-¥995.1m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Tax Provision
-¥990.6m
|
CAGR 3-Years
-86%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-11%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Tax Provision
-¥853.3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-6%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Tax Provision
-¥1B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-28%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Tax Provision
-¥270.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-126%
|
CAGR 10-Years
N/A
|
|
Pulike Biological Engineering Inc
Glance View
Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
See Also
What is Pulike Biological Engineering Inc's Tax Provision?
Tax Provision
-14.3m
CNY
Based on the financial report for Sep 30, 2025, Pulike Biological Engineering Inc's Tax Provision amounts to -14.3m CNY.
What is Pulike Biological Engineering Inc's Tax Provision growth rate?
Tax Provision CAGR 10Y
-1%
Over the last year, the Tax Provision growth was -30%. The average annual Tax Provision growth rates for Pulike Biological Engineering Inc have been 12% over the past three years , 9% over the past five years , and -1% over the past ten years .
